Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis-Reference-Cited by-同舟云学术

Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis

Published:2020-02-14 Issue: Volume: Page:
ISSN:
Container-title:General Session Abstracts
language:
Short-container-title:

Author:

Yau Christina,van der Noordaa Marieke,Wei Jane,Osdoit Marie,Reyal Fabien,Hamy Anne-Sophie,Lae Marick,Martin Miguel,del Monte Maria,Boughey Judy C,Gould Rebekah,Wesseling Jelle,Steenbruggen Tessa,van Seijen Maartje,Sonke Gabe,Edge Stephen,Sammut Stephen-John,Provenzano Elena,Abraham Jean,Hall Peter,Graham Ashley,Mackintosh Lorna,Cameron David,Wang Alice,Sharma Priyanka,Cole Kimberly,Pusztai Lajos,Kim Mi-Ok,van ‘t Veer Laura,Esserman Laura,Symmans W. Fraser,

Publisher

American Association for Cancer Research

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive Factors of Neoadjuvant Chemotherapy Response in Breast Cancer Validated by Three Anatomopathological Scores: Residual Cancer Burden, Chevallier System, and Tumor-Infiltrating Lymphocytes;Cureus;2024-04-30

2. Treatment optimization in early triple negative breast cancer;Expert Review of Anticancer Therapy;2023-10-03

3. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy;Investigational New Drugs;2023-04-12

4. Improving prediction of response to neoadjuvant treatment in patients with breast cancer by combining liquid biopsies with multiparametric MRI: protocol of the LIMA study – a multicentre prospective observational cohort study;BMJ Open;2022-09

5. Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective;Current Oncology;2022-06-06